[Botulinum toxin treatment in children]

Area of Science:

• Neurology
• Pediatrics
• Pharmacology

Context:

• Botulinum toxin type A (BoNT-A) has been used in pediatric patients for nearly two decades.
• Its primary indication is spastic equinus gait in cerebral palsy.
• Emerging uses include idiopathic toe-walking, pain management, drooling, and torticollis.

Purpose:

• To review the established and emerging indications for botulinum toxin type A in pediatric patients.
• To assess the safety and tolerability profile of botulinum toxin type A in children.
• To highlight the established efficacy for specific pediatric neuromuscular conditions.

Summary:

• Botulinum toxin type A is approved for treating spastic equinus gait in children over two years old.
• Despite being a potent neurotoxin, it demonstrates a favorable safety profile in pediatric populations.
• Adverse events are infrequent and generally mild, such as bruising or temporary muscle weakness, with increased risk of generalized events at higher doses.

Impact:

• Botulinum toxin type A offers a valuable therapeutic option for various pediatric conditions.
• Understanding its safety and efficacy supports expanded clinical application.
• This review provides insights for clinicians managing pediatric patients with neuromuscular disorders.